A new analysis highlights how antibody–oligonucleotide conjugates (AOCs) are advancing targeted therapeutics, tracing today’s platform development back to the “magic bullet” concept. The piece describes how modern AOCs aim to couple target recognition with payload delivery, supporting more precise intervention across disease areas where conventional biologics can be limited by distribution or mechanism. The discussion frames the technology’s evolution around conjugate design—linking binding to downstream activity—while pointing to current momentum toward tighter control of where and how therapeutics engage biological targets. For platform developers, the article reflects continuing interest in engineered conjugates as a route to increased specificity and functional potency.